Effe839 Posted - 41 minutes ago

$SGMT That -9% deep was a sweet buy 🤭

valueforme Posted - 17 hours ago

$SGMT C'mon Thierry, time to show your kung fu here

Stocks4thought Posted - 21 hours ago

$SGMT Crooks running the tables. Nothing more- computers vs humans or retail.

ElonMustLoveYou Posted - 1 day ago

$SGMT Oppenheimer sets $30 target on Sagimet Biosciences shares

valueforme Posted - 1 day ago

$SGMT Jay Olson, Oppenheimer Very thoughtful guy. Here is an example of his obesity names coverage - https://www.biotechtv.com/post/jay-olson-august-8-2024 And he called VKTX last year. So, $30 from Jay is pretty nice

cats44ever Posted - 1 day ago

$SGMT Thanks for posting Quantumup; don't know why they came out with the research note after hours.... much greater effect before market.

Quantumup Posted - 1 day ago

Oppenheimer🏁 $SGMT Outperform/$30. $MDGL $IVA $VKTX $ALGS ETNB AKRO LLY NVO Oppenheimer said in its research note: We initiate coverage of Sagimet Biosciences Inc. ( $SGMT ) with an Outperform rating and $30 PT. We see an underappreciated opportunity for lead asset denifanstat, a first-in-class fatty acid synthase (FASN) inhibitor, in metabolic dysfunction-associated steatohepatitis (#MASH) expected to reach ~$15B in market potential. We anticipate a near-term catalyst upon $SGMT raising ~$200M additional capital for ongoing Ph3 registrational trials by leveraging denifanstat's competitive profile based on Ph2b data. We see $SGMT as ultimately benefiting from MDGL's build-out of the MASH market as diagnosis rates and reimbursement improve. Our coverage of the MASH and obesity markets informs our optimistic view. Separately, the Ascletis partnership could provide additional value creation with Ph3 readouts for denifanstat in glioblastoma (GBM) expected in 1H25 and acne in 2H25.

cats44ever Posted - 1 day ago

$SGMT Don't want anyone to misread me; I'm extremely positive on this company & expect great results from the Ascletis Acne trial ending in 2Q 2025. All of the Denifanstat cancer trials were longshots... the GBM Brain Cancer, Small Cell Lung Cancer, Prostate Cancer, Breast Cancer & Colon Cancer trials. Still, the possibility exists/existed for some kind of success & breakthrough that would turn Deni into a wonderdrug with huge price appreciation... still hoping for that with the Acne trial, but have to be patient for the next 6 months. For now, I'll restrict myself to shorting Jan 5 puts for short term gratification (!).

Dark_Horse_Investments Posted - 1 day ago

$SGMT I personally assign zero value for sgmt on this trial. I am in on this for MASH and would say that the intrinsic value is well ahead of $4.72 - i venture to say that the company on the low end is worth $300 million. With this in mind, what is your theory on the oncology trial. I cannot find any updates... THX in advance

cats44ever Posted - 1 day ago

$SGMT We were told this summer to expect interim results in Q4 2024... but now (stated at the Piper conference), it's 'sometime in 2025'. The clinical trial site shows they ended enrollment as of 10/31/24, with only 136 out of the expected 180 patients that were supposed to participate in the trial; study end pushed back from 12/24 to 6/25. This despite a pdf 11/8/24 presentation from Ascletis stating that there would be 180 trial subjects & interim results due out by year end, but now... that presentation has been pulled (or is no longer available in English).

cats44ever Posted - 1 day ago

$SGMT $SGMT Something not quite right with the Ascletis GBM cancer trial.

kthart Posted - 1 day ago

$SGMT only down 10% in the first three hours? Sheeet might as well drop it to $2.2 in the next couple weeks if goldmuck sux is still shorting

Peterson28 Posted - 1 day ago

$SGMT Going to close the 4.77 gap on daily. Then go back up to 6.

valueforme Posted - 1 day ago

$SGMT Stop loss fishing

rational1 Posted - 2 days ago

$sgmt and there it is. MM's dropped it from $5.50 this a.m. to fill the gap on less than 100K shares. Nasdaq is crooked & I am close to swearing off any further investment dollars in their rigged system. Must remember to sell on the next positive news bounce.

rational1 Posted - 3 days ago

$SGMT MM push is on to fill the small gap @ $5.17 from last week. Market is rigged in case you had any doubts.

nastento Posted - 3 days ago

$SGMT love how they're getting pressure from everyone about financing lol I'm sure it complicated

kthart Posted - 3 days ago

$SGMT Happel says they are extremely fortunate to have so much interest, everything on the table, minimal dilution blah blah blah...anyone curious what they come up with? lol

valueforme Posted - 3 days ago

$SGMT The most important part of today's conference. Everything is on the table and dilution minimization is key

valueforme Posted - 4 days ago

$SGMT I was asked in the comments which funding scenario is the worst, and my answer is not surprisingly " public offering" Let me share what my dream scenario is. It is called a "biohaven-like" asset sale. How it works is described here - https://www.insidearbitrage.com/2024/01/inhibrx-acquisition-structured-like-the-biohaven-deal-merger-arbitrage-mondays/ Basically, in my dream scenario - MASH interested acquirer buys Sagimet with Denifanstat, but another FASN molecule TVB-3567 goes to "new Sagimet" with all the current cash on hand that Sagimet has now. This cash is enough to fund TVB-3567 in acne to approval, Dave said that at UBS conference - new Sagimet is a traded public company - we get let's say $25 per share as a distribution for old Sagimet+ 0.8 share of new Sagimet for every share of old Sagimet.

valueforme Posted - 4 days ago

$SGMT Piper Sandler conft tomorrow, do not forget. Nothing interests me at this point but financing. Announce the financing deal tomorrow morning, Dave, and then talk through the terms during the conference https://ir.sagimet.com/events/event-details/piper-sandler-36th-annual-healthcare-conference

valueforme Posted - 4 days ago

$SGMT I think we'll see 2 transactions announced the same day: - selling synthetic royalty for 100M (e.g. HealthCare Royalty Partners) - classic debt for 100M (e.g. SLR Life Science) Recent precedent of such funding from 2 different sources announced the same day - GERN https://www.businesswire.com/news/home/20241107070171/en/Geron-Corporation-Announces-Up-to-375-Million-in-Funding-with-Royalty-Pharma-and-Pharmakon-Advisors

valueforme Posted - 4 days ago

$SGMT In the meantime, synthetic royalty (royalties for non-approved drugs) deals are growing like crazy recently. Since November 1, 2024: SNDX, GERN, KALV, ASND

valueforme Posted - 4 days ago

$SGMT This is another way how financing of phase 3 might end up - classic debt or convertible debt

valueforme Posted - 4 days ago

$SGMT

nastento Posted - 4 days ago

$SGMT

Tjcmd Posted - 11/29/24

$SGMT Has the funding been decided on?

Stocks4thought Posted - 11/29/24

$SGMT $5.84 and we will start the journey over $6 again@@# ot $ALT $S

Stocks4thought Posted - 11/29/24

$SGMT El Chopostick- aligning perfect with $6 and every body likes six................ ot $VKTX $ALT $BWAY $

Stocks4thought Posted - 11/29/24

$SGMT $7 soom ot $SLNO $VKTX $ALT $BWAY deeply discounted because of funding event---------not gonna discount- and more commissions for IB's on higher pps. See ya